Dose-escalated Radiotherapy to 82 Gy for Prostate Cancer Following Insertion of a Peri-rectal Hydrogel Spacer: 3-Year Outcomes From a Phase II Trial

被引：0
|
作者：
Richie, Jerome P.
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1028 / 1028
页数：1
相关论文
共 35 条
  • [21] Clinical Outcomes after Proton Partial-Breast Radiotherapy for Early-Stage, Hormone Receptor-Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial
    Choi, I. J.
    Prabhu, K., Jr.
    Hartsell, W. F.
    Sinesi, C. C.
    Vargas, C. E.
    Benda, R. K.
    Cahlon, O.
    Chang, A. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E19 - E19
  • [22] Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial
    Choi, Isabelle
    Prabhu, Kiran
    Hartsell, William F.
    DeWees, Todd
    Sinesi, Christopher
    Vargas, Carlos
    Benda, Rashmi K.
    Cahlon, Oren
    Chang, Andrew L.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 37 : 71 - 77
  • [23] Toxicity and Patient Reported Quality of Life after PSMAPET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial
    Spohnfr, S. K. B.
    Gainey, M.
    Kamps, M.
    Jilg, C. A.
    Gratzke, C.
    Sigle, A.
    Mix, M.
    Ruf, J.
    Buerkle, S.
    Sprave, T.
    Wiehle, R.
    Serpa, M.
    Benndorf, M.
    Zschaeck, S.
    Ghadjar, P.
    Baltas, D.
    Kirste, S.
    Zamboglou, C.
    Grosu, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S95 - S95
  • [24] Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
    Poettgen, C.
    Gkika, E.
    Stahl, M.
    Abu Jawad, J.
    Gauler, T.
    Kasper, S.
    Trarbach, T.
    Herrmann, K.
    Lehmann, N.
    Joeckel, K-H
    Lax, H.
    Stuschke, M.
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [25] Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
    C. Pöttgen
    E. Gkika
    M. Stahl
    J. Abu Jawad
    T. Gauler
    S. Kasper
    T. Trarbach
    K. Herrmann
    N. Lehmann
    K.-H. Jöckel
    H. Lax
    M. Stuschke
    Radiation Oncology, 16
  • [26] 10-Year-Results of the prospective German-Austrian Phase II Multicenter study for risk-adapted Radiotherapy of localized Prostate Cancer with a moderate Dose Escalation from 70 to 74 Gy
    Goldner, G.
    Bombosch, V.
    Becker, G.
    Wachter, S.
    Glocker, S.
    Feldmann, H.
    Bamberg, M.
    Poetter, R.
    Molls, M.
    Geinitz, H.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 37 - 38
  • [27] Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update
    Hudson, John M.
    Loblaw, Andrew
    Mcguffin, Merrylee
    Chung, Hans T.
    Tseng, Chia-Lin
    Helou, Joelle
    Cheung, Patrick
    Szumacher, Ewa
    Liu, Stanley
    Zhang, Liying
    Deabreu, Andrea
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2024, 198
  • [28] 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group
    Dearnaley, D.
    Syndikus, I.
    Mossop, H.
    Birtle, A.
    Bloomfield, D.
    Cruickshank, C.
    Graham, J.
    Hassan, S.
    Khoo, V.
    Logue, J.
    Mayles, H.
    Money-Kyrle, J.
    Naismith, O.
    Panades, M.
    Patterson, H.
    Scrase, C.
    Staffurth, J.
    Tremlett, J.
    Griffin, C.
    Hall, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S712 - S712
  • [29] Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial
    Dearnaley, David P.
    Griffin, Clare
    Syndikus, Isabel
    Khoo, Vincent
    Birtle, Alison Jane
    Choudhury, Ananya
    Ferguson, Catherine
    Graham, John
    O'Sullivan, Joe
    Panades, Miguel
    Rimmer, Yvonne L.
    Scrase, Christopher D.
    Staffurth, John
    Cruickshank, Clare
    Hassan, Shama
    Pugh, Julia
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Dearnaley, David
    Syndikus, Isabel
    Mossop, Helen
    Khoo, Vincent
    Birtle, Alison
    Bloomfield, David
    Graham, John
    Kirkbride, Peter
    Logue, John
    Malik, Zafar
    Money-Kyrle, Julian
    O'Sullivan, Joe M.
    Panades, Miguel
    Parker, Chris
    Patterson, Helen
    Scrase, Christopher
    Staffurth, John
    Stockdale, Andrew
    Tremlett, Jean
    Bidmead, Margaret
    Mayles, Helen
    Naismith, Olivia
    South, Chris
    Gao, Annie
    Cruickshank, Clare
    Hassan, Shama
    Pugh, Julia
    Griffin, Clare
    Hall, Emma
    LANCET ONCOLOGY, 2016, 17 (08): : 1047 - 1060
1234